Group is a late stage biotechnology company focused on developing products based on its proprietary understanding of the regulation of cellular energy processes.
presently derives revenue from the sale of proprietary ingredients to skin care manufacturers and is developing a proprietary line of therapeutic skin care products.
does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.
The interview will cover topics including Avicena
Group's market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.
We are pleased that AL-08/celecoxib slowed deterioration in ALS- Functional Score compared to the other treatment and believe that results of this trial highlight the potential of this combination treatment for ALS patients," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena
Boston Medical Technologies, and Avicena
We are excited about the results of this HD-02 study in Huntington's disease and are pleased to have identified the optimal dose for further evaluation in next-year's Phase III trial," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena